Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones

Biochimie

Volumn 85, Issue 12, 2003, Pages 1219-1230

  Smith, S A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adipocyte; Adiponectin; Inflammation; Insulin resistance; Non esterified free fatty acids; Peroxisome proliferator activated receptor ; Plasminogen activator inhibitor 1; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALITRETINOIN; GLUCOSE TRANSPORTER 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; TRIACYLGLYCEROL;

ADIPOCYTE; BODY FAT; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES CONTROL; DIABETOGENESIS; DRUG MECHANISM; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIGAND BINDING; LIPID METABOLISM; LIPOLYSIS; PROTEIN PHOSPHORYLATION;

EID: 0347931775     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biochi.2003.10.010     Document Type: Conference Paper

References (84)

1. Zimmet P.Z., McCarty D.J., Courten M.P. The global epidemiology of non-insulin dependent diabetes mellitus and the metabolic syndrome. J. Diabetes Complications. 11:1997;60-68.
2. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 339:1998;229-234.
3. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview, Diabetes Care. 15:1992;318-368.
4. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14:2003;137-145.
5. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
6. Lebovitz H.E., Banerji M.D., Chaiken R.L. The relationship between type II diabetes and syndrome X. Curr. Opin. Endocrinol. Diabetes. 2:1995;307-312.
7. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 102:2000;42-47.
8. Lehman J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor gamma (PPARgamma). J. Biol. Chem. 270:1995;12953-12956.
9. Jowsey I.R., Murdock P.R., Moore G.B.T., Murphy G.M., Smith S.A., Hayes J.D. Prostaglandin D2 synthase enzymes and PPAR are co-expressed in mouse 3T3-L1 adipocytes and human tissues. Prostaglandins Lipid Mediators. 70:2003;267-284.
10. Smith S.A. Peroxisome proliferator activated receptors (PPAR) and the regulation of mammalian lipid metabolism. Biochem. Soc. Trans. 30:2003;1086-1090.
11. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
12. Mukherjee R., Jowe L., Croston G.E., Paterniti J.R.J. Identification, characterisation, and tissue distribution of human peroxisome proliferator activated receptor (PPAR) isoforms PPARγ2 versus PPAR 1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 272:1997;8071-8076.
13. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.-P., Staels B., Auwerx J., Laville M., Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1997;1319-1327.
14. Guisti V., Verdumo C., Suter M., Gaillard R.C., Burckhardt P., Pralong F. Expression of peroxisome proliferator-activated receptor-1 and peroxisome proliferator-activated receptorγ2 in visceral and subcutaneous adipose tissue of obese women. Diabetes. 52:2003;1673-1676.
15. Willson T.H., Cobb J.E., Cowan D.J., Wiethe R.W., Cirrera I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., Lehman J.M. The structure activity relationship between peroxisome-proliferator activated receptor gamma agonism and the antihyperglycaemic activity of thiazolidinediones. J. Med. Chem. 39:1996;665-668.
16. Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M.D., Moller D.E., Berger J. Molecular cloning, expression and characterisation of human peroxisome proliferator activated receptors γ1 and γ2. Biochem. Biophys. Res. Commun. 224:1996;431-437.
17. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehman J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and. Proc. Natl. Acad. Sci. USA. 94:1997;4318-4323.
18. Debril M.-B., Renaud J.-P., Fajas L., Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptorγ J. Mol. Med. 79:2001;30-47.
19. Frohnert B.I., Hui T.Y., Bernlohr D.A. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J. Biol. Chem. 274:2000;3970-3977.
20. Kim H., Kim J., Kim S., Cha J., Kim K., Ahn Y. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes. 49:2000;1517-1524.
21. Baumann C.A., Chokshi N., Saltiel A.R., Ribon V. Cloning and characterization of a functional peroxisome proliferator activator receptor-responsive element in the promoter of the CAP gene. J. Biol. Chem. 275:2000;9131-9135.
22. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and anitiatherogenic factor, by nuclear receptors. Diabetes. 52:2003;1655-1663.
23. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Hayes W.S., Plumpton C., Macphee C.H., Smith S.A. Resistin is expressed in human macrophages and is directly regulated by PPARγ activators. Biochem. Biophys. Res. Commun. 300:2003;472-476.
24. Hofmann C., Lorenz K., Braithwaite S.S., Colca J.R., Palazuk B.J., Hotamisligil G.S., Spiegelman B.M. Altered gene expression for tumor necrosis factor- and its receptor during drug and dietary modification of insulin resistance. Endocrinology. 134:1994;264-270.
25. Zhang E., Graziano M.P., Doebber M.D., Leibowitz S., White-Carrington D.M., Szalkowski P.J., Hey M., Wu C.A., Cullinam C.A., Bailey P., Lollman B., Frederich R., Flier J.S., Strader C.D., Smith R.G. Down regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. 271:1996;9455-9459.
26. Teruel T., Smith S.A., Peterson J., Clapham J.C. Synergistic activation of UCP-3 expression in cultured fetal rat brown adipocytes by PPARα and PPARγ ligands. Biochem. Biophys. Res. Commun. 273:2000;560-564.
27. Aubert J., Champigny O., Saint-Marc P., Negrel R., Collins S., Ricquier D., Ailhauld G. Upregulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem. Biophys. Res. Commun. 238:1997;606-611.
28. Young P.W., Cawthorne M.A., Coyle P.J., Holder J.C., Holman G.D., Kozka I.J., Lister C.A., Smith S.A. Repeat treatment of obese mice with BRL 49653, a novel and potent insulin sensitiser, enhances insulin action in white adipocytes: association with increased insulin binding and cell-surface glucose transporter, (GLUT-4) as measured by photoaffinity labelling. Diabetes. 44:1995;1087-1092.
29. Rieusset J., Auwerx J., Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. 265:1999;265-271.
30. Sewter C.P., Blows B., Vidal-Puig A., O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPARγ and RXRα agonists. Diabetes. 51:2002;718-723.
31. Barroso I., Gurnell M., Crowley V.E.F., Agostini M., Schwabe J.W., Soos M.A., Li Maslen G., Williams T.D.M., Lewis H., Schafer A.J., Chatterjee V.K.K., O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature. 402:1999;880-883.
32. Ciaraldi T.P., Gilmore A., Olefsky J.M., Goldberg M., Heidenreiach K.A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 39:1990;1056-1062.
33. Fulgencio J.-P., Kohl C., Girard J., Pegorier J.-P. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes. 45:1996;1556-1562.
34. Park K.S., Ciaraldi T.P., Abrams-Carter L., Mudaliar S., Nikoulina S.E., Henry R.E. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J. Clin. Endocrinol. Metab. 83:1998;1636-1643.
35. Arner P. Free fatty acids - do they play a central role in type 2 diabetes? Diabetes Obes. Metab. 3:2001;11-19.
36. Arner P. Regional adiposity in man. J. Endocrinol. 155:1997;191-192.
37. Farese R.V. Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. Am. J. Physiol. Endocrinol. Metab. 283:2002;E1-E11.
38. Peraldi P., Xu M., Spiegelman B.M. Thiazolidinediones block tumor necrosis factor - induced inhibition of insulin signaling. J. Clin. Invest. 100:1997;1863-1869.
39. Souza S.C., Yamamoto M.T., Franciosa M.D., Lien P., Greenberg A.S. BRL 49653 blocks lipolytic actions of tumor necrosis factor alpha: a potential new insulin-sensitising mechanism for thiazolidinediones. Diabetes. 47:1998;691-695.
40. Miles P.D.G., Romeo O.M., Higo K., Cohen A., Rafaat K., Olefsky J.M. TNF-α induced insulin resistance in vivo and its prevention by troglitazone. Diabetes. 46:1997;1678-1683.
41. Tordjman J., Chauvet G., Quette J., Beale E.G., Forest C., Antoine B. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J. Biol. Chem. 278:2003;18785-18790.
42. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., Digby J.E., Sewter C.P., Lazar M.A., Chatterjee K.K., O'Rahilly S. Activators of peroxisomal proliferator activated receptor gamma have depot-specific effects on human pre-adipocyte differentiation. J. Clin. Invest. 100:1997;3149-3153.
43. Van Harmelen V., Dicker A., Ryden M., Hauner H., Lonnqvist F., Naslund E., Arner P. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes. 51:2002;2029-2036.
44. Virtanen K.A., Hallsten K., Parkkola R., Janatuinen T., Lonnqvist F., Viljanen T., Ronnemaa J., Knuuti R., Lonnroth P., Nuutila P. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 52:2003;283-290.
45. Berger J., Tanen M., Elbrecht A., Hermanowski-Vosatka A., Moller D.E., Wright S.D., Thieringer R. Peroxisome proliferator activated receptor ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem. 276:2001;12629-12635.
46. Stewart P.M., Tomlinson J.W. Cortisol, 11 beta hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol. Metab. 13:2002;94-96.
47. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294:2001;2166-2170.
48. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., Umesono K., Akanuma Y., Fujiwara T., Horikoshi H., Yazaki Y., Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose mass in obese Zucker rats. J. Clin. Invest. 101:1998;1354-1361.
49. Boden G., Cheung P., Mozzoli M., Fried S.K. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism. 52:2003;753-759.
50. Hori H., Sasaoka T., Ishihara H., Wada T., Murakami S., Ishiki M., Kobayashi M. Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes. 51:2002;2387-2394.
51. Clement S., Krause U., Desmedt F., Tanti J.F., Behrends J., Pesesse X., Sasaki T., Penninger J., Doherty M., Malaisse W., Dumont J.E., Marchand-Brustel Y.L., Erneux C., Hue L., Schurmans S. The lipid phosphatase SHIP-2 controls insulin sensitivity. Nature. 409:2001;92-97.
52. Baumann C.A., Ribon V., Kanzaki M., Thurmond D.C., Mora S., Shigematsu S., Bickel P.E., Pessin J.E., Saltiel A.R. CAP defines a second signaling pathway required for insulin-stimulated glucose transport. Nature. 407:2000;202-207.
53. Ribon V., Johnson J.H., Camp H.S., Saltiel A.R. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptorγ activation stimulates expression of the CAP gene. Proc. Natl. Acad. Sci. 95:1998;14751-14756.
54. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86:2001;280-288.
55. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., Peterson K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
56. Guan H.-P., Li Y., Jensen M.V., Newgard C.B., Steppan C.M., Lazar M.A. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8:2002;1122-1128.
57. Tanaka T., Itoh H., Doi K., Fukunaga Y., Hosoda K., Shintani M., Yamashita J., Chun T.-H., Inoue M., Masatsuga K., Sawad N., Saito T., Inoue G., Nishimura H., Yoshimasa Y., Nakao K. Down regulation of peroxisome proliferator-activated receptorγ expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia. 42:1999;702-710.
58. Oakes N.D., Camilleri S., Furler S.M., Chisholm D.J., Kraegen E.W. Mechanisms of liver and muscle insulin resistance induced by high-fat feeding. Metabolism. 6:1997;935-942.
59. Schmitz-Pfeiffer C., Browne C.L., Oakes N.D., Watkinsn A., Chisholm D.J., Kraegen E.W., Biden T.J. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes. 46:1997;169-178.
60. Itani S.I., Pories W.J., MacDonald K.G., Dohm G.L. Increased protein kinase C theta in skeletal muscle of diabetic patients. Metabolism. 50:2001;553-557.
61. Jacob S., Machann J., Rett K., Brechtel K., Volk A., Renn W., Maerker E., Matthaei S., Schick F., Claussen C.-D., Haring H.-U. Association of increased intramyocellular lipid content with insulin resistance in lean non-diabetic offspring of type 2 diabetic subjects. Diabetes. 48:1999;1113-1119.
62. Seppälä-Lindroos A., Vehkavaara S., Häkkinen A.-M., Goto T., Westerbacka J., Sovijärvi A., Halavaara J., Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87:2002;3023-3028.
63. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., Doddrell D.M. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetes. Obes. Res. 10:2002;1008-1015.
64. Schmitz-Pfeiffer C., Oakes N.D., Browne C.L., Kraegen E.W., Biden T.J. Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653. Am. J. Physiol. 273:1997;E915-E921.
65. Oakes N.D., Kennedy C.J., Jenkins A.B., Laybutt D.R., Chisholm D.J., Kraegen E.W. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes. 43:1994;1203-1210.
66. Miyazaki Y., He H., Manadrino L.J., DeFronzo R.A. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes. 52:2003;1943-1950.
67. 3 is defective in muscle in type 2 diabetes and impaired glucose tolerance. Amelioration by rosiglitazone and exercise. Diabetes. 52:2003;1926-1934.
68. Ukkola O., Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J. Mol. Med. 80:2002;696-702.
69. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., Eto K., Yamashita T., Kamon J., Satoh H., Yano W., Nagai R., Kimura S., Kadowaki T., Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277:2002;25863-25866.
70. Motoshima H., Wu X., Sinha M.K., Hardy V.E., Rosato E.L., Barbot D.J., Rosato F.E., Goldstein B.J. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 87:2002;5662-5667.
71. Yang W.-S., Jeng C.-Y., Wu T.-J., Tanaka S., Funahashi T., Matsuzawa Y., Wang J.-P., Chen C.-L., Tai T.-Y., Chuang L.-M. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 25:2002;376-380.
72. Banerjee R.R., Lazar M.A. Resistin: molecular history and prognosis. J. Mol. Med. 81:2003;218-226.
73. McTernan C.L., McTernan P.G., Harte A.L., Levick P.L., Barnett A.H., Kumar S. Resistin, central obesity and type 2 diabetes. Lancet. 359:2002;46-47.
74. Harte A., McTernan P., Rajkumar C., Leah A., Barnett A., Smith S., Kumar S. TNFα mediates the insulin-mediated increase in angiotensinogen and angiotensin II production and its suppression by rosiglitazone in isolated human subcutaneous adipocytes. Diabetes. 52:2003;A82.
75. Raji A., Seely E.W., Bekins S.A., Williams G.H., Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 26:2003;172-178.
76. St. John Sutton M., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., Patel J., Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 25:2002;2058-2064.
77. Steinberg H.O., Paradisi G., Hook G., Crowder K., Cronin J., Baron A.D. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes. 49:2000;1231-1238.
78. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. 17:2003;7-12.
79. Natali A., Baldeweg S., Toschi E., Barbaro D., Capaldo B., Yudkin J., Ferrannini E. Rosiglitazone directly improves endothelial function in type 2 diabetic patients. Diabetes. 51:2002;A142.
80. Festa A., D'Agostino R., Mykkänen L., Tracy R.P., Zaccaro D.J., Hales C.N., Haffner S.M. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the insulin resistance atherosclerosis study (IRAS). Arteriosclerosis. 19:1999;562-568.
81. McTernan P., Eggo M.C., Smith S.A., Barnett A.H., Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes. Diabetes. 50:(Suppl. 2):2001;A275.
82. Freed M., Fuell D., Menci L., Heise M., Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 43:2000;A267.
83. Ouchi N., Kihar S., Funahashi T., Nakamura T., Nishida M., Kumada M., Okamaoto Y., Ohashi K., Nagaretani H., Kishida K., Nishizawa H., Maeda N., Kobayashi H., Hiraoka H., Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 107:2002;671-674.
84. Haffner S.M., Greeberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.